Vaxigrip (inactivated influenza vaccine (split virion)) / Sanofi - LARVOL DELTA

Seasonal Influenza Vaccine Effectiveness Study in Kenya (clinicaltrials.gov) - P=N/A | N=10000 | Completed | Sponsor: Gideon Emukule | Unknown status ➔ Completed

Trial completion • Infectious Disease • Influenza • Respiratory Diseases

Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais (clinicaltrials.gov) - P1/2 | N=290 | Active, not recruiting | Sponsor: Mahidol University | Trial primary completion date: Jun 2024 ➔ Mar 2024

Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases

Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza (clinicaltrials.gov) - P4 | N=1500 | Active, not recruiting | Sponsor: Medical University of Warsaw

New P4 trial • Genetic Disorders • Infectious Disease • Influenza • Obesity • Respiratory Diseases

Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind, non-inferiority, randomized controlled trial. (PubMed, Vaccine) - "Our findings support the non-inferiority of the FluGuard vaccine to the Vaxigrip vaccine regarding immunogenicity and safety."

Head-to-Head • Journal • Infectious Disease • Influenza • Respiratory Diseases

VAXXAIR: Vaccine Pandemic Preparedness Through Airway Immunology Characterization (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Chronic Obstructive Pulmonary Disease Trial Network, Denmark | Trial completion date: Dec 2025 ➔ Apr 2026 | Initiation date: Jan 2024 ➔ May 2024 | Trial primary completion date: Dec 2025 ➔ Apr 2026

Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases • CD4 • CD8

Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais (clinicaltrials.gov) - P1/2 | N=290 | Active, not recruiting | Sponsor: Mahidol University | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Influenza • Respiratory Diseases

Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais (clinicaltrials.gov) - P1/2 | N=290 | Recruiting | Sponsor: Mahidol University | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Influenza • Respiratory Diseases

Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais (clinicaltrials.gov) - P1/2 | N=290 | Not yet recruiting | Sponsor: Mahidol University | Trial completion date: Dec 2024 ➔ Mar 2025

Trial completion date • Infectious Disease • Influenza • Respiratory Diseases

VAXXAIR: Vaccine Pandemic Preparedness Through Airway Immunological Characterization (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Chronic Obstructive Pulmonary Disease Trial Network, Denmark

New P1 trial • Infectious Disease • Influenza • Respiratory Diseases • CD4

Peptide ILE-GLU-TRP (Stemokin) Potential Adjuvant Stimulating a Balanced Immune Response. (PubMed, Int J Pept Res Ther) - "A variety of modern approaches to developing prophylactic and therapeutic vaccines is growing. In almost all cases, adjuvants are necessary to obtain an effective immune response.This work investigated the possibility of using the pharmaceutical peptide drug Stemokin as an adjuvant stimulating a balanced Th1/Th2 response.A study was conducted to compare the activity of Stemokin versus the approved adjuvant Alhydrogel in a murine vaccination model with the approved VAXIGRIP® vaccine.The first proof-of-concept experimental study shows that the peptide Ile-Glu-Trp has the adjuvant vaccine properties and anti-HA IgG2a enhancing response, revealing a Th1- favoring balanced Th1/Th2 immunomodulation."

Journal • Hematological Disorders • Immune Modulation • Immunology • Infectious Disease • Inflammation